Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. 1993

N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
Third Department of Internal Medicine, Yamagata University School of Medicine, Japan.

Postprandial insulin secretion is modulated by both neural and humoral gastrointestinal insulinotropic factors in addition to the absorbed nutrient. To investigate the involvement of the potent insulinotropic hormones gastric inhibitory polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) in the postprandial hyperinsulinaemia of obesity, we examined the changes in plasma levels of GIP and tGLP-1 by an oral glucose tolerance test (OGTT) in nine normal subjects (controls), nine obese subjects without glucose intolerance (Group A), and six obese mild diabetic patients (Group B). Following the OGTT, plasma GIP levels in Group B were increased more markedly than those in the other two groups. Plasma levels of tGLP-1 were estimated by the difference between the values measured with the N-terminal directed antiserum (GLP-1NT) and those with the C-terminal directed antiserum (GLP-1 CT). Plasma levels of GLP-1 NT were increased in Group B, but decreased in the other two groups. Plasma GLP-1 CT levels were increased in all groups with the highest response in Group B. These results suggest that the combined augmentation of plasma GIP and tGLP-1 responses were involved in the delayed and considerable increases in plasma insulin after glucose ingestion in obese diabetic patients. Since tGLP-1 is suppressed in the hyperglycaemic hyperinsulinaemic state in normal subjects, the augmented tGLP-1 response appears to be characteristic of obese Type 2 diabetes.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D004763 Glucagon-Like Peptides Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms. Enteroglucagon,Enteroglucagons,Glucagon-Like Peptide,Glucagon-Like Polypeptide,Gut Glucagon,Glucagon-Like Polypeptides,Glucagon Like Peptide,Glucagon Like Peptides,Glucagon Like Polypeptide,Glucagon Like Polypeptides,Glucagon, Gut,Peptide, Glucagon-Like,Polypeptide, Glucagon-Like

Related Publications

N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
January 2016, International review of cell and molecular biology,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
February 2016, Current opinion in endocrinology, diabetes, and obesity,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
January 2018, Basic & clinical pharmacology & toxicology,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
December 2004, Diabetes,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
January 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
September 1998, The American journal of clinical nutrition,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
April 2009, The Journal of clinical endocrinology and metabolism,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
August 2010, The Journal of clinical endocrinology and metabolism,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
December 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
N Fukase, and M Igarashi, and H Takahashi, and H Manaka, and K Yamatani, and M Daimon, and M Tominaga, and H Sasaki
May 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!